logo

CUE

Cue Biopharma·NASDAQ
--
--(--)
--
--(--)
3.70 / 10
Netural

Capital flow data show a 7.4/10, classified as 'good', with Small-cap inflows slightly positive (0.5296) and block, Medium, Large, and Extra-large flows negative. This liquidity profile supports the idea of short-term buying interest but longer-term selling pressure. Analyst sentiment is overwhelmingly bullish, with one report issuing a Strong Buy rating and no Sell/Strong Sell recommendations. However, the historical win rate for this analyst is 0.0%, and the current price trend is falling (-12.13%). The Market Comprehensive Analysis indicates a mismatch between the falling price and the positive analyst expectation, suggesting potential for a mean-reversion bounce but also highlighting the need for vigilance.

FundamentalSentiment(3.7)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

100%

Buy

0%

Hold

0%

Sell

0%

Strong Sell

0%

Date2025-08-25
InstitutionLUCID CAPITAL MARKETS
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for CUE?
  • CUE holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.70/10 (Netural).